ASX - By Stock
|
EUR |
Re:
Ann: Options Prospectus
|
|
Bpharma
|
13 |
3.7K |
0 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
13
|
3.7K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
10 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
44
|
13K
|
10
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
9 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
44
|
13K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
44
|
13K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
6 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
44
|
13K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
11 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
44
|
13K
|
11
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
4 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
44
|
13K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Bpharma
|
4 |
1.8K |
7 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
4
|
1.8K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
7 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
44
|
13K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
3 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
44
|
13K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
3 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
44
|
13K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
5 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
44
|
13K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
Bpharma
|
44 |
13K |
10 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
44
|
13K
|
10
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Annual Report to shareholders
|
|
Bpharma
|
36 |
9.4K |
4 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
36
|
9.4K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce gearing up for Indonesian trials
|
|
Bpharma
|
9 |
2.9K |
5 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
9
|
2.9K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
Bpharma
|
22 |
7.4K |
9 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
22
|
7.4K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
Bpharma
|
22 |
7.4K |
5 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
22
|
7.4K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
Bpharma
|
22 |
7.4K |
20 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
22
|
7.4K
|
20
|
|
ASX - By Stock
|
GLV |
Re:
Woooooo Hoooooo go GLV :)$$&&&
|
|
Bpharma
|
182 |
47K |
0 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
182
|
47K
|
0
|
|
ASX - By Stock
|
LMG |
Re:
general discussion
|
|
Bpharma
|
1.9K |
823K |
0 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
1.9K
|
823K
|
0
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Update on BBB 33 Evaluation and Bolling 4 Drilling
|
|
Bpharma
|
220 |
76K |
0 |
04/04/24 |
04/04/24 |
ASX - By Stock
|
220
|
76K
|
0
|
|
ASX - By Stock
|
GLV |
Re:
Ann: Additional deeper targets identified in Bonito Prospect
|
|
Bpharma
|
47 |
10K |
2 |
02/04/24 |
02/04/24 |
ASX - By Stock
|
47
|
10K
|
2
|
|
ASX - By Stock
|
GLV |
Re:
Woooooo Hoooooo go GLV :)$$&&&
|
|
Bpharma
|
182 |
47K |
4 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
182
|
47K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
48 |
14K |
2 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
GLV |
Re:
Woooooo Hoooooo go GLV :)$$&&&
|
|
Bpharma
|
182 |
47K |
2 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
182
|
47K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
48 |
14K |
1 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
GLV |
Re:
Woooooo Hoooooo go GLV :)$$&&&
|
|
Bpharma
|
182 |
47K |
1 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
182
|
47K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
RCE General Discussion Topics
|
|
Bpharma
|
51 |
24K |
4 |
26/03/24 |
26/03/24 |
ASX - By Stock
|
51
|
24K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
Bpharma
|
38 |
10K |
2 |
21/03/24 |
21/03/24 |
ASX - By Stock
|
38
|
10K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
48 |
14K |
14 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
48
|
14K
|
14
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
48 |
14K |
1 |
20/03/24 |
20/03/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
Bpharma
|
38 |
10K |
4 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
38
|
10K
|
4
|
|
ASX - By Stock
|
EUR |
Re:
Where is the bottom ?
|
|
Bpharma
|
15 |
3.4K |
4 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
15
|
3.4K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.1K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.1K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.1K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.1K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.1K |
1 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.1K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.1K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.1K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
Bpharma
|
39 |
8.1K |
6 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
39
|
8.1K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
Bpharma
|
38 |
10K |
5 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
38
|
10K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
Bpharma
|
38 |
10K |
1 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
38
|
10K
|
1
|
|
ASX - By Stock
|
LMG |
Re:
general discussion
|
|
Bpharma
|
1.9K |
823K |
1 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
1.9K
|
823K
|
1
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Change of Director's Interest Notice
|
|
Bpharma
|
35 |
10K |
3 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
35
|
10K
|
3
|
|
ASX - By Stock
|
EUR |
Re:
Ann: Critical Metals Corp. Completes Business Combination
|
|
Bpharma
|
370 |
95K |
2 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
370
|
95K
|
2
|
|
ASX - By Stock
|
EUR |
Re:
Ann: Reinstatement to Quotation
|
|
Bpharma
|
15 |
4.8K |
5 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
15
|
4.8K
|
5
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.1K |
316K |
3 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.1K
|
316K
|
3
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.1K |
316K |
0 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.1K
|
316K
|
0
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.1K |
316K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.1K
|
316K
|
0
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.1K |
316K |
0 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.1K
|
316K
|
0
|
|
ASX - By Stock
|
EUR Lithium |
Re:
General Discussion
|
|
Bpharma
|
1.1K |
316K |
6 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
1.1K
|
316K
|
6
|
|
ASX - By Stock
|
BNL |
Re:
Ann: Change of Director's Interest Notice
|
|
Bpharma
|
22 |
6.2K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
22
|
6.2K
|
3
|
|